BPC-157 is one of the most-discussed compounds on the platform, and also one of
the most misunderstood. This monograph lays out what the compound actually is,
what the research literature does and does not show, and what to demand of a
vendor before evaluating any product.
Chemical identity & structure.
BPC-157 stands for "Body Protection Compound-157". It is a synthetic
pentadecapeptide — a chain of 15 amino acids, sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The sequence
corresponds to a partial fragment of a protein identified in human gastric
juice; BPC-157 itself does not occur in nature as a discrete molecule. It is
notable for being unusually stable in aqueous solution and in gastric acid,
which is why the research literature often refers to it as "stable gastric
pentadecapeptide BPC 157".
Mechanism of action.
The mechanisms described in the literature are still being characterized, and
should be read as hypothesized rather than settled. The most consistently
reported are: promotion of angiogenesis (new blood-vessel formation), reported
via upregulation of the VEGFR2 receptor pathway; modulation of the nitric oxide
system; and an interaction with growth-hormone-receptor expression in tendon
fibroblasts in cell-culture work. Cytoprotective and gut-mucosal effects are
also widely reported. Importantly, no single unifying mechanism has been
established.
Key research findings.
The preclinical literature — almost entirely rodent studies — reports effects
in models of tendon-to-bone healing, ligament and muscle injury, gastrointestinal
ulceration and inflammatory bowel models, and peripheral nerve injury. The
breadth of reported effects is itself a reason for caution: a compound reported
to help almost everything in animal models warrants a skeptical read until
human data exists.
The research / citation base.
This is the single most important section. **There are no published,
completed human clinical trials of BPC-157.** The evidence base is preclinical
and is dominated by work from a small number of research groups, principally in
Croatia (the Sikiric group). That does not make the findings wrong, but it does
mean the compound's human safety and efficacy profile is genuinely unknown.
Anyone presenting BPC-157 as a proven human therapy is overstating the
evidence.
Human clinical trial data.
No human clinical trial has established administration parameters for BPC-157; VialTalk does
not provide community-sourced dosing.
Quality & sourcing notes.
Because BPC-157 is a defined 15-mer, a meaningful COA should report identity
(mass spectrometry confirming the expected molecular weight) and purity (HPLC,
ideally ≥98%). Sequence-incorrect and underdosed product is a known problem in
this market. Treat any vial without a batch-specific COA as unverified.
*Research-use note: This monograph is an educational summary of the published
research literature. BPC-157 is not an approved drug; it is described here for
research context only. Nothing here is medical advice or a usage recommendation.*